Additional OS details for T-DM1

Roche (SIX:ROG; OTCQX:RHHBY) and its Genentech Inc. unit said T-DM1 led to median overall survival (OS) of 30.9 months vs. 25.1 months for Tykerb

Read the full 240 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE